Report: IPC Conference Presentation by Professor Mark Wilcox
Professor of Medical Microbiology – University of Leeds, Leeds Teaching Hospital, National Clinical Director AMR & IPC – NHS England and Lead on C. difficile – UKHSA
In a recent conference, Prof. Mark Wilcox shed light on the alarming increase in C. diff infections and the associated mortality rates. The speaker, an expert in the field, provided a comprehensive analysis of the current challenges and their potential causes. Through his thought-provoking presentation, he emphasized the need for a shift in focus to combat this persistent threat effectively. Let’s dive into the speaker’s insights and unravel the story of C. diff’s resurgence.
“The rather depressing situation is summarized here concerning CDI,” the speaker began, capturing the audience’s attention. He revealed a startling statistic—a 25% increase in C. diff incidents following years of plateau or decline. This surge primarily stemmed from hospital-onset cases, painting a grim picture of current affairs.
Mortality Rates and Unsettling Comparisons
Delving deeper, Prof. Mark focused on the mortality rates associated with C. diff. He acknowledged the limitations of crude mortality data but revealed an alarming trend. The rate, gradually decreasing, suddenly reversed from 13.5% to 14.9%. While this may seem marginal, the speaker emphasized, “Actually, it’s a 10% increase, which is bad.” To highlight the severity, he compared meningococcal meningitis, which evokes considerable public concern. Astonishingly, the mortality rate for C. diff surpassed that of meningococcal meningitis or sepsis.
Further complicating matters, he revealed the impact of a COVID-19 diagnosis on C. diff mortality. Individuals with a COVID-19 diagnosis in the 28 days before or after a C. diff infection faced even higher risks. The interaction between these two health challenges posed an additional threat, particularly for the elderly.
Unveiling the Mystery
The speaker delved into possible explanations for the surge in C. diff incidents. He dismissed the notion of significant changes in C. diff strains or quantitative antibiotic prescribing as primary drivers. Instead, he proposed a disheartening reality. “We have concentrated on controlling a respiratory virus, neglecting an enteric pathogen,” he lamented. The strain on healthcare systems, coupled with the inherent ability of C. diff to exploit weaknesses, had contributed to the current predicament.
Stability of C. diff Strains
Analysing data on C. diff strains, the speaker reassured the audience that the strains had not undergone significant changes. Despite marginal differences, the patterns remained stable throughout the pandemic. “C. diff strains have not changed. The increase in incidents is not due to a mutation or expansion of specific ribotypes,” he explained. The critical message was clear—C. diff itself had not transformed, but rather external factors were at play.
Exploring International Variances
Curiosity arose among the audience regarding the global impact of C. diff incidents. Prof. Mark acknowledged that the increase was not uniformly observed in all countries. Publications from Spain, the United States, and the Netherlands revealed varying results. Notably, the Netherlands reported a significant change in testing and sampling practices during the pandemic. These findings prompted speculation about ascertainment bias and the need for a closer examination of NHS data.
Ascertainment Bias and Testing Discrepancies
He addressed the issue of ascertainment bias, pointing out the discrepancy between Hospital Onset Diarrhoea rates and the number of samples submitted for C. diff testing. He asked the audience to reflect on the frequency of Hospital Onset Diarrhoea, which affected approximately one in 20 patients daily. Comparatively, the number of samples submitted for C. diff testing remained considerably lower. “We’re missing a lot of cases,” he stated, highlighting the need for improved surveillance and testing procedures.
The Bottom Line
Prof. Mark Wilcox enlightening presentation shed light on the rising incidents of C. diff infections and the associated challenges. The story of C. diff’s resurgence is a poignant reminder of the urgency to address this persistent threat. By acknowledging the neglect of an enteric pathogen amidst the battle against a respiratory virus, healthcare systems can redirect their focus and resources. Enhanced surveillance, testing procedures, and targeted interventions are essential to combatting C. diff effectively. Only through collective efforts can we hope to bring down the alarming mortality rates and protect vulnerable populations from the clutches of this formidable bacterium.
Reference
